SEARCH:   Advanced

Blood, 15 September 2005, Vol. 106, No. 6, pp. 2102-2104. Prepublished online as a Blood First Edition Paper on June 2, 2005; DOI 10.1182/blood-2005-03-0874. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-03-0874v1 106/6/2102    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Führer, M. Articles by Bender-Goetze, C. Search for Related Content PubMed PubMed Citation Articles by Führer, M. Articles by Bender-Goetze, C. Related Collections Immunobiology Red Cells Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  IMMUNOBIOLOGY Brief report Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival Monika Führer, Udo Rampf, Irith Baumann, Andreas Faldum, Charlotte Niemeyer, Gritta Janka-Schaub, Wilhelm Friedrich, Wolfram Ebell, Arndt Borkhardt, Christine Bender-Goetze, for the German/Austrian Aplastic Anemia Working Group From the Children's University Hospital, Department of Hematology and Oncology, Ludwig-Maximilians-University, Munich, Germany; the Department of Pathology, University of Erlangen, Erlangen, Germany; the Institut for Medizinische Biometrie, Epidemiologie und Informatik, Johannes Gutenberg University, Mainz, Germany; the Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University of Freiburg, Freiburg, Germany; the Children's University Hospital, Department of Hematology and Oncology, Hamburg, Germany; the Department of Pediatrics, University of Ulm, Ulm, Germany; and the Department of Pediatrics, Charite, Campus Virchow Klinikum, Humboldt University, Berlin, Germany. Severe acquired aplastic anaemia (SAA) is a life-threatening disease characterized by pancytopenia and hypoplastic bone marrow. Autologous T lymphocytes are thought to cause bone marrow failure by immune-mediated excessive apoptosis of stem and progenitor cells. The disease is subclassified into a severe (neutrophil count, > 0.2 x 109/L [> 200/µL]) and a very severe (< 0.2 x 109/L [< 200/µL]) (vSAA) form. We report the results of a prospective multicenter trial with a combined immunosuppressive regimen of cyclosporin A (CSA), anti-thymocyte globulin (ATG) and, in cases with neutrophil counts fewer than 0.5 x 109/L (< 500/µL), granulocyte colony-stimulating factor (G-CSF) for treatment of SAA in children. Children with vSAA showed a higher rate of complete response than did children with SAA (68% versus 45%; P = .009), as well as better survival (93% versus 81%; P < .001). Thus, in children with SAA a more severe disease stage at diagnosis indicates a favorable outcome with immunosuppressive therapy. (Blood. 2005;106:2102-2104) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: R. Gurion, A. Gafter-Gvili, M. Paul, L. Vidal, I. Ben-Bassat, M. Yeshurun, O. Shpilberg, and P. Raanani Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis Haematologica, May 1, 2009; 94(5): 712 - 719. [Abstract] [Full Text] [PDF] J. R. Passweg and A. Tichelli Immunosuppressive treatment for aplastic anemia: are we hitting the ceiling? Haematologica, March 1, 2009; 94(3): 310 - 312. [Full Text] [PDF] P. Scheinberg, C. O. Wu, O. Nunez, P. Scheinberg, C. Boss, E. M. Sloand, and N. S. Young Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study Haematologica, March 1, 2009; 94(3): 348 - 354. [Abstract] [Full Text] [PDF] A. Yoshimi, I. Baumann, M. Fuhrer, E. Bergstrasser, U. Gobel, K.-W. Sykora, T. Klingebiel, U. Gross-Wieltsch, M. M van den Heuvel-Eibrink, A. Fischer, et al. Immunosuppressive therapy with anti-thymocyte globulin and cyclosporine A in selected children with hypoplastic refractory cytopenia Haematologica, March 1, 2007; 92(3): 397 - 400. [Abstract] [Full Text] [PDF] J. C.W. Marsh Treatment of acquired aplastic anemia Haematologica, January 1, 2007; 92(1): 2 - 5. [Full Text] [PDF] A. Locasciulli, R. Oneto, A. Bacigalupo, G. Socie, E. Korthof, A. Bekassy, H. Schrezenmeier, J. Passweg, M. Fuhrer, and on the behalf of the Severe Aplastic Anemia Workin Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation Haematologica, January 1, 2007; 92(1): 11 - 18. [Abstract] [Full Text] [PDF] N. S. Young, R. T. Calado, and P. Scheinberg Current concepts in the pathophysiology and treatment of aplastic anemia Blood, October 15, 2006; 108(8): 2509 - 2519. [Abstract] [Full Text] [PDF] E. C. Guinan Aplastic Anemia: Management of Pediatric Patients Hematology, January 1, 2005; 2005(1): 104 - 109. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020